Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

The field of cytochrome P450 pharmacogenetics has progressed rapidly during the past 25 years. All the major human drug-metabolizing P450 enzymes have been identified and cloned, and the major gene variants that cause inter-individual variability in drug response and are related to adverse drug reactions have been identified. This information now provides the basis for the use of predictive pharmacogenetics to yield drug therapies that are more efficient and safer. Today, we understand which drugs warrant dosing based on pharmacogenetics to improve drug treatment. It is anticipated that, in the future, genotyping could be used to personalize drug treatment for vast numbers of subjects, decreasing the cost of drug treatment and increasing the efficacy of drugs and health in general. I estimate that such personalized P450 gene-based treatment would be relevant for 10-20% of all drug therapy.

[1]  A. Garrod The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article] , 1902, The Yale journal of biology and medicine.

[2]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[3]  J. Miners,et al.  Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. , 1993, Pharmacogenetics.

[4]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[5]  R. Kato,et al.  cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3). , 1989, Nucleic acids research.

[6]  R. Branch,et al.  Mephenytoin hydroxylation deficiency: Kinetics after repeated doses , 1984, Clinical pharmacology and therapeutics.

[7]  Y. Funae,et al.  A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). , 1998, Pharmacogenetics.

[8]  M. Dahl Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics , 2002, Clinical pharmacokinetics.

[9]  H. Echizen,et al.  Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin , 2003, The Pharmacogenomics Journal.

[10]  A. Daly,et al.  Pharmacogenetics of oral anticoagulants. , 2003, Pharmacogenetics.

[11]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[12]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[13]  M. Ingelman-Sundberg,et al.  Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. , 2002, Pharmacogenetics.

[14]  L. Balant,et al.  Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. , 1982, British journal of clinical pharmacology.

[15]  Michael Böhm,et al.  Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects , 2002, Clinical pharmacology and therapeutics.

[16]  U. Meyer,et al.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.

[17]  T. Chang,et al.  Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes , 2003, The Pharmacogenomics Journal.

[18]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[19]  M. I. Ngelman-Sundber Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001 .

[20]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[21]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[22]  M. Cronin,et al.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. , 2000, Journal of clinical psychopharmacology.

[23]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[24]  Robert L. Smith The Paton Prize Award. The discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences. , 2001, Toxicology.

[25]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[26]  Zhaoqian Liu,et al.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[27]  M. Eichelbaum,et al.  Influence of the defective metabolism of sparteine on its pharmacokinetics , 1979, European Journal of Clinical Pharmacology.

[28]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[29]  F. Sjöqvist,et al.  Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. , 1967, Life sciences.

[30]  J. de Leon,et al.  Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. , 2003, Journal of clinical psychopharmacology.

[31]  M. Dahl,et al.  Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. , 1997, Therapeutic drug monitoring.

[32]  Teruhiko Yoshida,et al.  Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population , 2004, Human mutation.

[33]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[34]  R. Weinshilboum Inheritance and drug response. , 2003, The New England journal of medicine.

[35]  B. Alexanderson,et al.  Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy , 1969, British medical journal.

[36]  H. Melhus,et al.  The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial , 2002, Journal of hypertension.

[37]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[38]  S. Sindrup,et al.  The pharmacogenetics of codeine hypoalgesia. , 1995, Pharmacogenetics.

[39]  M. Ingelman-Sundberg,et al.  Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.

[40]  M. Kennedy,et al.  Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. , 2003, Pharmacogenetics.

[41]  Shiew-Mei Huang,et al.  Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop , 2003, Journal of clinical pharmacology.

[42]  Munir Pirmohamed,et al.  Cytochrome P450 enzyme polymorphisms and adverse drug reactions. , 2003, Toxicology.

[43]  R. Kaiser,et al.  Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[45]  M. Oscarson Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[46]  R. Krishnamoorthy,et al.  Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese. , 1991, British journal of clinical pharmacology.

[47]  A. Motulsky Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.

[48]  E. Dickson,et al.  Genetics of Response to Proton Pump Inhibitor Therapy , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[49]  A. Kjellin,et al.  Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders , 2000, Alimentary pharmacology & therapeutics.

[50]  F. Guengerich,et al.  Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. , 1987, Biochemistry.

[51]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[52]  L. Maltais,et al.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.

[53]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[54]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[55]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[56]  L. Bertilsson,et al.  LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.

[57]  L. Bertilsson,et al.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study , 2003, European Journal of Clinical Pharmacology.

[58]  Zhaoqian Liu,et al.  Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[59]  G. Discombe Letter: Medical nemesis. , 1974, Lancet.

[60]  I. Dunham,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D , 1991 .

[61]  Magnus Ingelman-Sundberg,et al.  Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[62]  L. Bracco,et al.  The relevance of alternative RNA splicing to pharmacogenomics. , 2003, Trends in biotechnology.

[63]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[64]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[65]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[66]  Grethe Andersen,et al.  Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial , 1999, PAIN.

[67]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[68]  J. Benítez,et al.  Genetic basis for differences in debrisoquin polymorphism between a spanish and other white populations , 1994, Clinical pharmacology and therapeutics.

[69]  M. Ingelman-Sundberg,et al.  DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE , 1989, The Lancet.

[70]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[71]  M Ingelman-Sundberg,et al.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.

[72]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[73]  Gray Jg,et al.  LIVING AND DYING IN THE NINETEENTH CENTURY. , 1963 .

[74]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[75]  R. Brosens,et al.  CYP3A4, CYP3A5 and MDR‐1 Variant Alleles in The Dutch Caucasian Population , 2003 .

[76]  U. Yasar,et al.  Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.

[77]  F. Vogel Moderne Probleme der Humangenetik , 1959 .

[78]  J. Miners,et al.  Polymorphic hydroxylation of perhexiline in vitro. , 2003, British Journal of Clinical Pharmacology.

[79]  A. Paterson,et al.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.

[80]  R. Tyndale,et al.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.

[81]  L. H. Snyder Studies in Human Inheritance. IX, The Inheritance of Taste Deficiency in Man , 1932 .

[82]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[83]  A. Garrod The Incidence of Alkaptonuria: A study in Chemical Individuality , 1996, Nutrition reviews.

[84]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.